• Date: March 05, 2018
  • Place:
  • Hotel Crowne Plaza
  • Avinguda de Rius i Taulet, 1-3
  • Barcelona
  • show map

Barcelona will be the host city for the 11th Annual Conference of Biomedical Research Technology Platforms, which will be held on 5 and 6 March at the Hotel Crowne Plaza. The event will address the possibilities opened up by the latest genomic technologies in terms of advancing biomedical research and developing new treatments, as well as the importance of digitisation and data analysis in personalised medicine.

The conference programme includes four plenary sessions, one for each of the technology platforms: Innovative Medicines, Nanomedicine, Health Technology and Biotechnology Markets. The conference also offers several parallel sessions, including one covering the practical aspects of data sharing in biomedical research, and another addressing the new paradigms in clinical research, among others. The “la Caixa” Banking Foundation participates on 6 March in the session National and international financing for cooperation in the health sector.

The conference is run by the Spanish Technological Platform for Innovative Medicines (Farmaindustria), together with the Spanish Federation of Healthcare Technology Companies (FENIN), the Spanish Association of Biotech Companies (ASEBIO) and the Spanish Nanomedicine Platform (Nanomed Spain).

  • Registration form

Hotel Crowne Plaza, Barcelona

More events

July 03, 2019

The 3rd iPharma conference comes to London

The theme of this year’s edition will be “Pharma research for Industry demands”.

July 03, 2019

Back-to-back Horizon 2020 health partnering and info events in Brussels

Taking place on the 3 and 4 July, these events aim to provide health innovators and entrepreneurs with the latest information for the next round of Horizon 2020 calls.

June 25, 2019

MedFit innovation partnering event to be held in Lille

With more than 700 delegates expected to attend, the event will serve as an ideal meeting place for industry leaders, research institutions and start-ups.